Lucentis®
GoodRxRanibizumab · intravitreal injection
Injections & Implants
Approved uses
Neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization
0.5 mg (0.05 mL of the 10 mg/mL strength) intravitreally once a month; for myopic CNV, up to three months with retreatment as needed
The higher of the two strengths; myopic CNV is the only one with a defined stopping point
Diabetic macular edema and diabetic retinopathy
0.3 mg (0.05 mL of the 6 mg/mL strength) intravitreally once a month
The diabetic indications use the LOWER strength, 0.3 mg rather than 0.5 mg, at the same 0.05 mL volume
Contraindications
Ocular or periocular infections Hypersensitivity.
Available FormsIntravitreal injection, single-dose prefilled syringe delivering 0.05 mL: 0.5 mg (10 mg/mL) and 0.3 mg (6 mg/mL).
Mechanism of ActionRanibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF 110. VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Warnings & Precautions
Endophthalmitis and retinal detachment may follow intravitreal injection; monitor the patient after the injection. Increases in intraocular pressure have been seen both before and after injection. There is a potential risk of arterial thromboembolic events.
Common Side Effects
The most common adverse reactions (reported more frequently in LUCENTIS-treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP.
Pregnancy & LactationPregnancy: No adequate and well-controlled studies in pregnant women. Ranibizumab given to pregnant monkeys throughout organogenesis produced a low incidence of skeletal abnormalities at systemic exposures well above those expected from intravitreal dosing.
Lactation: No data on presence in human milk; a risk to the breastfed infant cannot be excluded.
Pediatric UseThe safety and effectiveness of LUCENTIS in pediatric patients have not been established.